We look forward to seeing you at one of our local, regional, or national events, or please join us at one of our upcoming webinars.

Eleview® upcoming events, conferences, and webinars

December 2018 Events

Date Title Location Register Online
12/1 ACG Regional Congress Nashville, TN Contact your rep to register
12/13 – 12/14 NYSGE Annual New York Course New York, NY n/a
12/13 NYSGE Lunch Symposia New York, NY Contact your rep to register

The list will be updated regularly. Or contact your rep for the latest events.

Back to Top

Register for our webinars through the Aries Physician Education Exchange (APEX)

APEX is dedicated to bringing you fresh perspectives from key opinion leaders in the field. To register for an online webinar, please select from the events above.

Aries Physician Educational Exchange logo

You are leaving EleviewUS.com to visit another Aries Pharmaceuticals, Inc. website.

Cancel Send Request


Eleview® submucosal injectable composition is intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions, prior to excision with a snare or endoscopic device.


Patients with known sensitivity to any of the components contained in Eleview®.


  • The endoscopist injecting Eleview® must be experienced in the administration technique.
  • The safety of Eleview® has not been established in pregnant or lactating women, or in children under 18 years of age.
  • Eleview® is provided in single-use ampoules. Eleview® should not be reused after the first opening. Any emulsion not injected during the procedure should not be reused for another endoscopic procedure.
  • Do not use if the primary packaging (ampoule) or secondary packaging (aluminum pouch) is damaged.
  • Do not use if the twist-off cap is damaged.
  • Do not use if the emulsion is not clear, shows any signs of opalescence, or contains floating or precipitated visible particles.
  • The product compatibility with other substances has not been tested.


Rarely, local bleeding and/or inflammatory reaction could occur which may or may not be associated with Eleview®.


The administered dose of Eleview® should be determined based on the dimensions of the lesion to be removed. Inject into the submucosa the amount of Eleview® needed to form a submucosal cushion of optimal height and shape for the lesion to be removed. During the procedure do not exceed a total dose of 50 mL per patient, either in single or in multiple administrations.

Please see Instructions for Use for complete Important Safety Information.